This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


trusted source


Novel combination therapy offers promising results for treatment-refractory hepatoblastoma

Novel combination therapy offers promising results for treatment-refractory hepatoblastoma
Graphical abstract. Credit: Journal of Hepatology (2024). DOI: 10.1016/j.jhep.2024.01.003

Hepatoblastoma (HB) is the most common liver cancer in children. Researchers and physicians in the field are concerned because in the last decade HB has been rising rapidly worldwide and has seen the most rapid increase among all pediatric solid tumors.

A team led by researchers at Baylor College of Medicine has been working on improving therapies for this devastating disease. They report in the Journal of Hepatology a novel treatment strategy that produced encouraging results in animal models.

"High-risk disease leads to high rates of relapse and mortality," said first author Dr. Andrés F. Espinoza, general surgery resident in Baylor's Michael E. DeBakey Department of Surgery.

"In this study, we investigated the potential benefits of a new combination therapy that included an inhibitor of the enzyme histone deacetylase (HDAC) present at elevated levels in HB cells," Espinoza said. "Previous studies have suggested that HDAC inhibitors may provide treatment options for HB, but there is no published preclinical data on such therapies."

To assess the effects of the novel combination therapy, the researchers developed a preclinical testing pipeline with clinically relevant HB models.

Identifying an effective new combination therapy

First, the researchers tested several HDAC inhibitors on their ability to kill patient-derived HB cell lines grown in the lab. They found that HDAC inhibitor panobinostat was the most effective at eliminating cancer cells.

The team then tested whether adding panobinostat to current chemotherapy regimens would improve . They screened these treatments in patient-derived spheroids, spherical cellular aggregates derived from human tumor samples. Their results show that adding panobinostat to the combination treatment including vincristine and irinotecan eliminated more than any of the other combinations.

Finally, they tested the new combination therapy of vincristine, irinotecan and panobinostat (VIP) in four aggressive animal models of HB the researchers had derived from high-risk, relapsed and treatment refractory HBs.

The molecular characterization of these tumors in the animal models showed that they conserved all mutations found in the human tumors of origin as well as other molecular markers present in patient tumor samples. This indicated that the tumors in the animal models closely matched those in the patients. Importantly, in contrast to other studies that tested treatments on small-sized tumors, this study tested VIP in large tumors.

"After just one week of therapy, the tumors that were treated with VIP had a significant decrease in volume and alpha fetoprotein levels, the tumor marker," said corresponding author Dr. Sanjeev A. Vasudevan, associate professor of surgery at Baylor.

"These findings are very encouraging as they suggest that VIP therapy may be a promising and effective option for patients with currently untreatable high-risk, relapsed or refractory HB."

More information: Andres F. Espinoza et al, A Novel Treatment Strategy Utilizing Panobinostat for High-Risk and Treatment-Refractory Hepatoblastoma, Journal of Hepatology (2024). DOI: 10.1016/j.jhep.2024.01.003

Citation: Novel combination therapy offers promising results for treatment-refractory hepatoblastoma (2024, February 21) retrieved 12 April 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Combination drug therapy shows promise for a treatment-resistant cancer


Feedback to editors